Spine Biologics Market Size To Reach $4.38 Billion By 2030

Spine Biologics Market Growth & Trends

The global spine biologics market size is expected to reach USD 4.38 billion by 2030, registering a CAGR of 5.08% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing incidence of spinal injuries. Prevalence of spinal deformities has been on a rise in developed and underdeveloped countries and this has resulted in an increase in the number of surgeries being carried. This has had a positive impact on the market for spine biologics.

Apart from this, growing awareness about numerous advantages of biologics in spine fusion surgeries, such as minimal postoperative time and ability to activate cellular growth, has also propelled the market. Biomaterials and bone graft substitutes are being adopted as the choice of treatment for spinal deformities. Increasing percentage of the elderly population suffering from spinal disorders and rising adoption of these products as a treatment method is anticipated to boost the market for spine biologics over the forecast period.

The geriatric population is more prone to spondylolisthesis and degeneration of disc. This, coupled with increasing number of trauma cases due to road accidents and sports injuries, is driving demand for spine biologics. According to the Open Access Journal for Minimally Invasive Surgery (MIS) published in 2018, minimally invasive techniques are being adopted for the treatment of a wide range of spine pathologies. Approximately 400,000 cases are performed in the U.S. annually and spine fusion has turned out to be one of the most commonly performed and well-established treatment options for spine trauma, degenerative disorders, tumors, and structural abnormalities.

 Request a free sample copy or view report summary: Spine Biologics Market Report

Spine Biologics Market Report Highlights

• The spinal allografts segment dominated the market and accounted for 58.62% of the global revenue in 2023. This dominance can be attributed to the numerous benefits associated with the usage of allografts.

• The hospital segment dominated the market in 2023. The segment is primarily driven by an increased number of spine fusion surgeries performed in these facilities.

• North America dominated the market and accounted for a 48.36% share in 2023. The growth of the market can be attributed to stable economic growth, increased adoption of minimally invasive surgeries, and rising prevalence of spine disorders such as disc-related issues, spinal stenosis, and spondylolisthesis.

• Asia Pacific is anticipated to witness the fastest growth in the market due to the presence of a large patient pool and growing awareness among patients and surgeons about the advantages of biologics.

Spine Biologics Segmentation

Grand View Research has segmented the spine biologics market report based on product, end-use and region:

Spine Biologics Product Outlook (Revenue, USD Million, 2018 - 2030)

• Spinal Allografts

  • Machined Bones Allograft

  • Demineralized Bone Matrix

• Bone Graft Substitutes

  • Bone Morphogenetic Proteins

  • Synthetic Bone Grafts

• Cell-based Matrix

Spine Biologics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Ambulatory Surgical Centers

Spine Biologics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• MEA

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Spine Biologics Market

• Stryker

• NuVasive, Inc.

• Orthofix

• DePuy Synthes (Johnson & Johnson)

• Exactech, Inc.

• Zimmer Biomet

• Arthrex, Inc.

• Medtronic

• Organogenesis Inc.

• Kuros Biosciences.